MedTrace Logo

Ablative Technique For Ovarian Preservation In Endometrioma

NCT07119060 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 332

Last updated 2026-03-19

No results posted yet for this study

Summary

The goal of this clinical trial is to compare pregnancy rates after different surgical treatments for endometriomas in adult women who have one or more ovarian cysts (endometriomas) larger than 2 cm requiring surgery. The main questions it aims to answer are:

How many women become pregnant within 24 months after surgery ? What are the birth rates and different types of pregnancies (natural, with fertility treatments, and those continuing beyond 12 weeks)? How often do the endometriomas come back after surgery? What surgery-related complications occur? How do pain levels change after treatment?

Researchers will compare different surgical treatment groups to see if one approach results in better pregnancy outcomes and fewer complications.

Participants will:

Be randomly assigned to different surgical treatment groups Undergo surgery for their endometriomas and endometriosis Attend follow-up visits at 3 months and 24 months after the procedure Have their pregnancy outcomes, pain levels, and potential complications monitored throughout the study period

Conditions

Interventions

PROCEDURE

Cystectomy

Surgical removal of the endometrioma by gently pulling the cyst wall away from the ovarian tissue (divergent traction technique)

PROCEDURE

plasma vaporization

It consists of destroying the cyst wall (vaporization) using plasma energy

PROCEDURE

Sclerotherapy

Ethanol sclerotherapy destroys the endometriotic tissue lining the inner wall of the cyst through prolonged contact with 96% alcohol

Sponsors & Collaborators

  • Clinique Tivoli Ducos

    lead OTHER

Principal Investigators

  • Horace ROMAN · IFEMEndo - Clinique Tivoli

  • Adrien CRESTANI · IFEMEndo - Clinique Tivoli

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
43 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-18
Primary Completion
2034-07-31
Completion
2035-01-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07119060 on ClinicalTrials.gov